Botanical species · safety record

Prunus persica

The EFSA Compendium of Botanicals holds 9 constituent measurements for Prunus persica. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Prunus persica (L.) Batsch

9Constituent measurements

0Safety records

3Cited sources

357Licensed products (Canada)

Also recorded as

Persica vulgaris Mill.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 357 licensed products naming Prunus persica as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Source material stated

Dried ripe seeds
Edible fruit part
Fruit
Fruit concentrate
Fruit flesh
Kernel
Kernel (stir-baked)
Leaf

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Amygdalin	Seed	Solvent extraction	5.792 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Cyanogenic glycosides	Seed	Solvent extraction	≤ 1044.45 Microgram/gram	Chromatographic tests	No resolvable identifier
Cyanogenic glycosides	Seed	Solvent extraction	≥ 442.72 Microgram/gram	Chromatographic tests	No resolvable identifier
Lariciresinol	Unspecified	Solvent extraction	≤ 80 Microgram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Lariciresinol	Unspecified	Solvent extraction	≥ 41 Microgram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Pinoresinol	Unspecified	Solvent extraction	≥ 131 Microgram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Pinoresinol	Unspecified	Solvent extraction	≤ 186 Microgram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Secoisolarisiresinol	Unspecified	Solvent extraction	≥ 18 Microgram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Secoisolarisiresinol	Unspecified	Solvent extraction	≤ 27 Microgram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Milder, Ivon E. J., Arts, Ilja C. W., van de Putte, Betty., Venema, Dini P., Hollman, Peter C. H. Lignan contents of Dutch plant foods: A database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. British journal of nutrition, 2005, vol. 93, no. 3, p. 393-402.
Cho, Hye-Jeon., Do, Byung-Kyung., Shim, Soon-Mi., Kwon, Hoonjeong., Lee, Dong-Ha., Nah, Ahn-Hee., Choi, Youn-Ju., Lee, Sook-Yeon. Determination of cyanogenic compunds in edible plants by ion chromatography. Toxicological research (seoul, republic of korea), 2013, vol. 29, no. 2, p. 143-147.
Bolarinwa, Islamiyat F., Orfila, Caroline., Morgan, Michael R. A. Development and application of an enzyme-linked immunosorbent assay (ELISA) for the quantification of amygdalin, a cyanogenic glycoside, in food. Journal of agricultural and food chemistry, 2014, vol. 62, no. 27, p. 6299-6305.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature